Revista de Gastroenterología del Perú - Volumen 21, Nº1 2001


REFERENCIAS BIBLIOGRÁFICAS

1. World Health Organization. Expanded Programme on immunization. UPDATE November 1989.

2 World Health Organization. Progress in the control of viral hepatitis: Memorandum from WHO Meeting. Bull World Organ 1988; 66: 443-445.

3 LJUNGGREN KE,PATARROYO ME,ENGLE R et al. Viral hepatitis in Colombia: A study of the (hepatitis of the Sierra Santa Marta,,. Hepatology 1985; 5: 299-304.

4 FONSECA JC, FERREIRA LC, SILVA-GUERRA ALP, et al. Hepatite fulminante e febre negra de Lábrea: Estudo de 5 casos procedentes de Codajas, Amazonas, Brasil. Rev Soc Bras Med Trop 1983; 16: 144-47.

5 HADLER SC. MONSON M, PONZETTO A et al. Delta virus infection and severe hepatitis. Ann Intern Med 1984: 100: 339-349.

6 RIZZETO M, VERNE G, RECHIS S. Chronic hepatitis in carriers of hepatitis B surface antigen. With intrahepatic expression of delta antigen. An active and progressing disease unreponsive to immune supressive treatament. Ann Intern Med 1983; 98: 437.

7 FARCI P, SMEDILE A, LAVARINI C. et al. Delta hepatitis in inapparent carriers of hepatitis B surface antigen. A disease simulating acute B hepatitis progressive to chronicity. Gastroenterology 1983; 85: 669-673.

8 ARICO S. Clinical significance of antibody to the hepatitis delta virus in symptom less HbsAg carriers. Lancet 1985: ii: 356-8

9 FONSECA, JCF, GAYOTTO LCC, FERREIRA LCL et al. Labrea hepatitis- hepatitis B and Delta antigen expresion in liver tissue: report of three autopsy cases. Rev Inst Med Trop Sao Paulo 1985; 17: 224

10 FONSECA JCF, SIMONETTI S, SCHATZMAYR H, CATEJON M, CESARIO A AND SIMONETTI J. Prevalence of infection with hepatitis delta virus (HDV) among carriers of hepatitis B surface antigen in Amazonas State, Brasil. Trans R Soc Trop Med Hyg 1988; 82: 469

11 MENDEZ M, ARCE M, SANCHEZ S y col. Prevalencia de marcadores serológicos de hepatitis vírica en diversos grupos de población del Perú. Bol Of Sanit Panam 1989; 106: 127-138.

12 RUÍZ CHAVEZ R. Marcadores serológicos de hepatitis viral en la región amazónica del Perú: Estudio de una población representativa. Diagnóstico 1989; 24: 5-9.

13 VILDOSOLA H, FARFAN G, COLAN E et al. Prevalencia del antígeno de superficie del virus de hepatitis B en población general de Costa, Sierra y Selva del Perú. Reporte preliminar. Rev Gastroen Perú 1990; 10: 96-101

14 COLICHON Y A. Distribución seroepidemiológica de la Hpetitis B y hepatitis Delta en diferentes comunidades indigenas de la Selva Peruana (Tesis doctoral). Lima, Perú: Universidad Peruana Cayetano, Heredia, 1989.

15 CABEZAS C, ANAYA E. Transmisión horizontal de hepatitis viral B de población desplazada de una zona hiperendémica a sus contactos en una zona de baja endemicidad. Bol Soc Per de Enf Infecc y Trop 1995; 4: 28.

16 INDACOCHEA S, GOTUZZO E,DE LA FUENTE J, PHILIPS I, WHIGNAL S. Elevada prevalencia de hepatitis B y Delta en el valle interandino de Abancay. Revista Médica Herediana 1991; 2: 168-71.

17 CABEZAS C, GOTUZZO E. ESCAMILLA J, IHILIPS I. Prevalencia de marcadores serológicos de hepatitis viral A, B y Delta en escolares aparentemente sanos de Huanta (Perú). Rev Gastroent Perú 1994; 14: 123-134

18 ENCINAS E,PALACIOS 0, CAMPOS C y col. Contribución a la clínica y anatomía de la hepatitis epidémica aguda en Abancay. Ann de la Fac de Med 1956; XXXIX: 1-72.

19 GASTELUMENDI R. BURSTEIN M, LEON BARUA R. Contribución al estudio de la hepatitis viral endemo-epidémica en Abancay. Ann de la Fac de Med 1960; XLIII: 629-50.

20 ROLANDO N, FIGUEROA R, TAKANO J, GUILLEN C, LIZARRAGA J Y HAVE J. Estudio clínico, bioquímico, y anatomopatológico de los portadores de antígeno de superficie de la hepatitis B en Abancay. Diagnóstico 1983; 12: 5-17.

21 FLORES A, GOTUZZO E, CABEZAS C, WATTS D, HOLGADO W. Estudio demográfico de la hepatitis B y Delta en la ciudad de Abancay-Apurimac. Bol Soc Per de Enf Infecc y Trop 1995; 4: 26.

22 INDACOCHEA S, GOTUZZO E. Mortalidad por Hepatitis viral B en Abancay. Rev Gastroent Perú 1993; 13: 173-77.

23 SZMUNESS W, STEVEN CE. HARLEY EJ et al. Hepatitis B vaccine demostration of efficacy in a controlled clinical trial in a high-risk population in the United States. N EngI J Med 1980; 303: 833-841.

24 WONG VCW, IP HMH, REESINK HW et al. Prevention of the HBsAg and HBeAg by administration of hepatitis B vaccine and hepatitis immunoglobulin. Lancet 1984; i: 921-926.

25 DEL CAHNO R, GRROSHEIDE PM, VOOGD M, HUISMAN VM, HEIJTINK RA, SCHALM SW. Immunogenicity of 20 ug of recombinant DNA hepatitis B vaccine in healthy neonates: A comparison of three different vaccination schedules. Journal of Medical Virology 1993; 41: 30-34.

26 PÉTRE J, VAN WIJNWNDAELE F, DE NEYS B, CONRATH K. VAN OPSTAL 0 et al. Development of Hepatitis Vaccine from transformed yeast cells. Postgraduate Medical Journal 1987: 63 (Suplement 2): 7381

27 HALL JA, INSKIP HM, LOIK F, CHOTARD J, VALL MAYANS M. Hepatitis B vaccine in the expanded programme of immunisation: The Gambian experience. Lancet 1989; ii: 1057-60.

28 PAÑO/WHO. Progress report on hepatitis B vaccination in the Americas. En: Report of the PAÑO Workshop on Viral Hepatitis Pre-Meeting to the 10 th Annual Meeting of the EPI/Polio TAG. Rio de Janeiro, Brasil, March 15, 1992.

29 WHITTLE HC, INSKIP H,HALL AJ,MENDY M, DOWNES R, HOARE S. Vaccination against hepatitis B and protection against chronic viral carriage in the Gambia. Lancet 1991; 337: 747-50

30 ANDRE FE. ZUCKERMAN A. Review: Protective of hepatitis B Vaccine in neonates. Journal of Medical Virology 1994; 44: 144-151.

31 CHOTARS J, INSKIP H, JALL AJ, LOIK F. et al. The Gambia Hepatitis Intervention Study: Follow-Up of a Cohort of Children Vaccinated against hepatitis B. The Journal of Infec Diseases 1992; 166: 764-8

32 MAÑONEY FJ, WOODRUFF BA, ERBEN J, COLEMAN PJ, REID EC et al. Effect of a Hepatitis B vaccination Program on Prevalence of hepatitis B Virus Infecction. The Journal of Infectious Diseases 1993; 167: 203-7.

33 World Health Organization. Progress in the control of viral hepatitis: Memorandum from a WHO meeting. Bull WHO 1988; 66: 443-455.

34 TABOR E, CAIRNS J, GERETY R, BAYLEY A. Nine Year Follow-Up Study of a plasma-Derived Hepatitis B Vaccine in a Rural African Setting 1993; 40: 204-209.

35 PRINCE AM. Revaccination against hepatitis B. Lancet 1991; 338: 61 (Letter).

36 Ministerio, de Salud Dirección General de Salud de las Personas. Sub-Programa de Inmunizaciones- Manual de Control de Enf enfermedades Prevenibles por vacunas. Perú 1995.

37 COURSAGET P, YVONNET B, RELYVELD EH, BARRES JL, DIOP-MAR I, CHIRON JP. Simultaneus administration of diphtheria-tetanus-pertussis-polio and hepatitis B vaccines in a simplified immunisation programme: immune responses to diphtheria toxoid, tetanus toxoid, pertussis and hepatitis B surface antigen. Infect immun 1986; 51: 784-87

38 SCHEIERMANN N, GESEMANN M, MAURER C, JUST M AND BERGER R. Persistence of antibodies after immunization with a recombinant yeast-derived hepatitis B vaccine following two different schedules. Vaccine 1990; 8 (Supplement): S44-S46.

39 ANDRE FE. Overview of a 5 year clinical experience with a yeast-derived hepatitis B vaccine. Vaccine 1990; 8 (Supplement): S74-S78.

40 DA VILLA G. PIAZZA M. IORIO R, PICCIOTI TO L,PELUSO P, DE LUCA G AND BASILE B. A Pilot Model of vaccination Against Hepatitis B Virus Suitable for Mass Vaccination Campaigns in Hyperendemic areas. Journal of Medical Virology 1992: 36: 274-278

41 BLOOM BS, HILLMAN AL, FENDRICK AM. A Reappraisal of Hepatitis B Virus Vaccination Strategies Using Cost-Effectiveness Analysis. Annals of Internal Medicine 1993; 118: 298-306.

42 MANGTANI P, HALL AJ, NORMAND CEM. Hepatitis B vaccination: The cost effectiveness of alternative strategies in England and Wales. J Epidemiol Community Health 1995; 49: 238-244.

43 FEMANDEZ BR. RIVERO D, ECHEVARRÍA B, MACHADO I. Costo beneficio de la vacunación contra hepatitis B en trabajadores de hospitales de Venezuela. Bol Of Sanit Panam 1991; 111: 16-23.

44 MAUSKOPF JA, BRADLEY CJ. FRENCH MT. Benefit Cost Analysis of hepatitis for Occupationally Exposed Workers. Journal Of Ocupational Medicine 1991; 33: 691-98.

REGRESAR AL ARTÍCULO